Journal
PATHOGENS
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/pathogens11020237
Keywords
oseltamivir derivatives; influenza virus; influenza antiviral; oseltamivir-resistant
Categories
Funding
- Health and Medical Research Fund-Commissioned Programme for Influenza Research [INF-CUHK-2]
- Research Fund Secretariat of the Food and Health Bureau, The Government of the Hong Kong Special Admirative Region
Ask authors/readers for more resources
Influenza virus is a major public health challenge characterized by high morbidity and mortality. Oseltamivir is commonly used as an antiviral, but resistant strains have been detected. This study designed and synthesized two new compounds that showed significant antiviral activity against both seasonal and oseltamivir-resistant strains. These compounds have the potential to be an important addition to the arsenal of antiviral drugs.
Characterized by the high morbidity and mortality and seasonal surge, the influenza virus (IV) remains a major public health challenge. Oseltamivir is commonly used as a first-line antiviral. As a neuraminidase inhibitor, it attenuates the penetration of viruses through the mucus on the respiratory tract and inhibits the release of virus progeny from infected cells. However, over the years, oseltamivir-resistant strains have been detected in the IV surveillance programs. Therefore, new antivirals that circumvent the resistant strains would be of great importance. In this study, two novel secondary amine derivatives of oseltamivir CUHK326 (6f) and CUHK392 (10i), which bear heteroaryl groups of M2-S31 proton channel inhibitors, were designed, synthesized and subjected to biological evaluation using plaque assay. Influenza A virus (A/Oklahoma/447/2008, H1N1), influenza B viruses (B/HongKong/CUHK33261 /2012), an oseltamivir-resistant influenza A virus (A/HongKong/CUHK71923/2009, H1N1) and an oseltamivir-resistant influenza B virus (B/HongKong/CUHK33280/2012) were included in the antiviral effect assessment compared to oseltamivir carboxylate (OC). Both novel compounds significantly reduced the plaque size of seasonal IV A and B, and performed similarly to OC at their corresponding half-maximal inhibitory concentration (IC50). CUHK392 (10i) functioned more effectively than CUHK326 (6f). More importantly, these compounds showed an inhibitory effect on the oseltamivir-resistant strain under 10 nM with selective index (SI) of >200.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available